Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.

Department of Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, Maryland 21205, USA.
Nature medicine (Impact Factor: 28.05). 07/2008; 14(7):762-6. DOI: 10.1038/nm1777
Source: PubMed

ABSTRACT Highly active antiretroviral therapy (HAART) can control HIV-1 replication, but suboptimal treatment allows for the evolution of resistance and rebound viremia. A comparative measure of antiviral activity under clinically relevant conditions would guide drug development and the selection of regimens that maximally suppress replication. Here we show that current measures of antiviral activity, including IC(50) and inhibitory quotient, neglect a key dimension, the dose-response curve slope. Using infectivity assays with wide dynamic range, we show that this slope has noteworthy effects on antiviral activity. Slope values are class specific for antiviral drugs and define intrinsic limitations on antiviral activity for some classes. Nucleoside reverse transcriptase inhibitors and integrase inhibitors have slopes of approximately 1, characteristic of noncooperative reactions, whereas non-nucleoside reverse transcriptase inhibitors, protease inhibitors and fusion inhibitors unexpectedly show slopes >1. Instantaneous inhibitory potential (IIP), the log reduction in single-round infectivity at clinical drug concentrations, is strongly influenced by slope and varies by >8 logs for anti-HIV drugs. IIP provides a more accurate measure of antiviral activity and in general correlates with clinical outcomes. Only agents with slopes >1 achieve high-level inhibition of single-round infectivity, a finding with profound implications for drug and vaccine development.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Implications of bioinformatics on the development of epitope-based vaccines are described.•A compilation of useful bioinformatics tools for vaccine development is presented.•Implications on developing vaccines against hypervariable viruses are described.•Perspectives for the field are identified.
    Journal of Biomedical Informatics 11/2014; DOI:10.1016/j.jbi.2014.11.003 · 2.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigate the phenomenon of HIV eradication at the early stage of the infection and evaluate the chance of the eradication with a mathematical model. We employ an extracellular deterministic model of the HIV infection dynamics and modify the model to include the pharmacokinetics and pharmacodynamics of antiretroviral HIV drugs. In addition we consider clinical experiments for the prevention of HIV infection using pre-exposure chemoprophylaxis treatment. Exploiting the mathematical model we implement the experiment numerically. The study in this paper is supported by the clinical results and provides a theoretical explanation for the results. The result suggests that the protocol of the experiment eradicates the virus in HIV infected patients.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During HIV-1 reverse transcription, there are increasing opportunities for nucleos(t)ide (NRTI) or non-nucleoside (NNRTI) reverse transcriptase inhibitors to stop elongation of the nascent viral DNA. In addition, RT inhibitors appear to influence the kinetics of vDNA synthesis differently. While cell-free kinetic inhibition constants have provided detailed mechanistic insight, these assays are dependent on experimental conditions that may not mimic the cellular milieu. Here we describe a novel cell-based strategy to provide a measure of the intrinsic inhibition efficiencies of clinically relevant RT inhibitors on a per-stop-site basis. To better compare inhibition efficiencies among HIV-1 RT inhibitors that can stop reverse transcription at any number of different stop sites, their basic probability, p, of getting stopped at any potential stop site was determined. A relationship between qPCR-derived EC50 values and this basic probability, p, enabled determination of p by successive approximation. On a per-stop-site basis, tenofovir (TFV) exhibited 1.4-fold greater inhibition efficiency than emtricitabine (FTC), and as a class, both NRTIs exhibited an 8- to 11-fold greater efficiency than efavirenz (EFV). However, as more potential stops-sites were considered, the probability of reverse transcription failing to reach the end of the template approached equivalence between both classes of RT inhibitors. Overall, this novel strategy provides a quantitative measure of the intrinsic inhibition efficiencies of RT inhibitors in the natural cellular milieu and thus may further understanding of drug efficacy. This approach also has applicability for understanding the impact of viral polymerase-based inhibitors (alone or in combination) in other virus systems. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 11/2014; DOI:10.1128/AAC.04163-14 · 4.45 Impact Factor

Full-text (2 Sources)

Available from
Sep 15, 2014